AroCell AB (publ), a vitro diagnostics company, develops and markets blood and urine sample test products for use in the treatment of breast, prostate, and bladder cancers. The company provides AroCell TK 210 ELISA, an immunoassay kit for the determination of human Thymidine Kinase 1 protein concentration in blood samples; and UBC Rapid for diagnosing and monitoring bladder cancer patients. It also offers TUBEX TF, an in vitro diagnostic test for the detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Stock data | 2024 | Change |
---|---|---|
Price | $0.053876671401283244 | N/A |
Market Cap | $12.41M | N/A |
Shares Outstanding | 230.36M | N/A |
Employees | 26.00 | N/A |